Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of swertiamarin in preparation of medicine for treating ischemic stroke

A technology for ischemic stroke and ericin, which is used in the field of use of scleroside in the preparation of drugs for the treatment of ischemic stroke, so as to reduce the apoptosis rate, reduce the calcium ion concentration, reduce the effect of apoptosis

Active Publication Date: 2021-08-17
NINGXIA MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its protective effect on neurological injury diseases such as cerebral ischemic nerve injury and neurodegenerative diseases has not been reported so far, and its development as a drug for the treatment of ischemic stroke has extremely high potential value and social significance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of swertiamarin in preparation of medicine for treating ischemic stroke
  • Application of swertiamarin in preparation of medicine for treating ischemic stroke
  • Application of swertiamarin in preparation of medicine for treating ischemic stroke

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Use of swertiamarin in the preparation of medicines for treating ischemic stroke, wherein the molecular structural formula of swertiamarin is shown in formula (1)

[0031]

[0032] Ischemic stroke is ischemic stroke in the acute stage or repair stage, the single application dose of swertiamarin in the cells is 0.1 μmol / l, and the dosage form of the drug is the powder injection dosage form allowed by pharmacy.

Embodiment 2

[0034] Use of swertiamarin in the preparation of medicines for treating ischemic stroke, wherein the molecular structural formula of swertiamarin is shown in formula (1)

[0035]

[0036] Ischemic stroke is ischemic stroke in the acute stage or repair stage, the single application dose of swertiamarin in the cells is 1 μmol / l, and the dosage form of the drug is an injection dosage form allowed by pharmacy.

Embodiment 3

[0038] The use of swertiamarin in the preparation of medicines for the treatment of ischemic stroke, its molecular structural formula is shown in formula (1)

[0039]

[0040] Ischemic stroke is ischemic stroke in the acute stage or repair stage, the single application dose of swertiamarin in the cells is 10 μmol / l, and the dosage form of the drug is an oral dosage form permitted by pharmacy.

[0041] The effect of embodiment 1 to 3 can be verified by following cell experiments:

[0042] 1. Experimental materials

[0043] 1.1 Experimental reagents and instruments

[0044] PC-12 cells (Kunming Institute of Zoology), 1640 medium, FBS were from gibco, all chemical reagents for preparing EBSS were from Suleibao, methazolium blue (MTT) was purchased from Guangzhou Chemical Reagent Factory; microplate reader was purchased from Thermo company; lactate dehydrogenase LDH, malondialdehyde MDA, superoxide dismutase SOD, catalase CAT, glutathione peroxidase GPx, ROS assay kit: produc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the use of swertiamain (Swertiamain) in the preparation of drugs for the treatment of ischemic stroke, and the protection of swertiamain on PC-12 cells after oxygen-glucose deprivation is explored by establishing an oxygen-glucose deprivation model Effect and possible mechanism of action, the experimental results of the present invention show that after oxygen-glucose deprivation reperfusion, it reduces intracellular active oxygen, malondialdehyde content, improves superoxide dismutase, catalase, glutathione In addition, swertiamarin can reduce the apoptosis rate of PC-12 cells and the expression of apoptosis-related proteins, and reduce the apoptosis of PC12 cells caused by oxygen-glucose deprivation-reperfusion, It shows that the protective effect of swertiamarin may be related to anti-oxidation and anti-apoptosis. These results prove that swertiamarin has a protective effect on ischemic injury.

Description

technical field [0001] The invention relates to the application of swertiamarin, in particular to the application of swertiamarin in the preparation of medicines for treating ischemic stroke. Background technique [0002] Ischemic brain disease, also known as ischemic stroke, has become one of the major fatal and disabling diseases worldwide, seriously threatening human life and health. After ischemic stroke, clinical thrombolytic therapy will cause further brain damage, that is, cerebral ischemia-reperfusion injury. Currently, there are few clinical treatment measures for neuronal injury caused by ischemia-reperfusion. Neuroprotective drugs for blood reperfusion injury are still a research hotspot. [0003] The mechanism of cerebral ischemia-reperfusion injury is complex, and researches suggest that brain cell injury caused by interruption of cerebral blood flow and reperfusion is a multi-factor, multi-mechanism, rapid malignant cascade reaction. Its main pathogenesis inc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P9/10
CPCA61K31/7048A61P9/10
Inventor 余建强王慧刘宁李玉香彭晓东
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com